Review - Haymarket Media Group

More documents

Recommendations

Info

TABLE OF CONTENTS INVITED PRESENTATIONS OF PEER-REVIEWED CLINICAL RESEARCH ® Trends in Breast Cancer 8 Weekly Paclitaxel Improves Disease-Free and 10 Overall Survival in the Adjuvant Treatment of Breast Cancer REVIEW The New England Journal of Medicine Rachel E. Raab, MD; Joseph A. Sparano, MD ➢ Montefiore-Einstein Cancer Center, Bronx, New York Optimizing Taxane Therapy for Patients 15 With Primary Breast Cancer: What Are the Lessons Learned? COMMENTARY Lawrence N. Shulman, MD ➢ Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston, Massachusetts HER2 Status and Inflammatory Breast Cancer: 17 Evidence of Prognostic Significance and Trastuzumab Efficacy REVIEW Cancer Shaheenah Dawood, MRCP(UK), MPH; Ana M. Gonzalez-Angulo, MD ➢ Dubai Hospital, U.A.E. Inflammatory Breast Cancer: Still a Challenge 20 COMMENTARY Nancy U. Lin, MD ➢ Dana-Farber Cancer Institute, Boston, Massachusetts Risk of Local Recurrence for Breast Cancer Subtypes 23 Defined by ER, PR, and HER2 Status CASE STUDY Paul L. Nguyen, MD, et al ➢ Harvard Medical School, Boston, Massachusetts 4 The American Journal of Hematology/Oncology November 2008 • Vol 7 • Supplement 5 ® Editor in Chief, Medical Oncology Lawrence N. Shulman, MD Editor in Chief, Surgical Oncology Douglas J. Schwartzentruber, MD, FACS Associate Editor, Radiation Oncology Marcus E. Randall, MD Publisher Steve Svec 201-799-4874 Steve.svec@haymarketmedia.com Senior Editorial Director Kristin Lee Siyahian Kristinlee.siyahian@haymarketmedia.com Editorial Director Kristen Olafson Kristen.olafson@haymarketmedia.com Senior Copy Editor Bjarne Hansen Production Editor Rick Maffei Art Director Robert Mancuso Production Inquiries Leslie Carsman 646-638-6075 Director of Sales Chad Holloway 201-799-4878 Chad.holloway@haymarketmedia.com Circulation Department ajhosubs@haymarketmedia.com For reprints contact: Greg Rucker 212-221-9595 ext 105 Greg.rucker@parsintl.com Haymarket Media Inc. CEO Lee Maniscalco CFO Michael Kriak Associate Publishing Director Jeff Forster Group Editor Tanya Gregory, PhD
LettertoOurReaders Dear Colleague, Each year, we devote an issue to breast cancer. This month, we address several recent reports on advances in the field and in the care of patients with this disease. We are still learning how to optimally administer cytotoxic chemotherapy; the manuscript by Sparano and colleagues is critical in comparing the two principal taxanes available to us, as well as two different schedules of administration. Survival and toxicity data taken together are essential for establishing optimal taxane therapy in the adjuvant setting for both standard care and future clinical trials. Continued exploration into differences in the biologic subtypes of breast cancer determined by hormone receptor status and HER2 status is helping us to better understand the disease, and what optimal therapies will be, based on these subgroups of patients. The manuscript by Dawood and colleagues exploring HER2 status in inflammatory breast cancer and the manuscript by Nguyen and colleagues looking at biologic subtypes associated with local and distant recurrence after breast-conserving therapy are examples of these advances. Once a year, it is worthwhile to review the substantial progress we have made in our understanding of breast cancer and the treatment of this disease. Survival rates have risen dramatically over the last two decades, partly due to improved screening, but also due to better therapies for these patients. We appreciate your continued interest in The American Journal of Hematology/Oncology and trust that you will benefit from the information presented here. Sincerely, Lawrence N. Shulman, MD Editor in Chief, Medical Oncology November 2008 • Vol 7 • Supplement 5 7
Page 1: ajho.com November 2008 • Vol 7
Page 5 and 6: hand-foot syndrome, 23.9% vs 31.1%;
Page 7 and 8: Figure Paclitaxel 175 mg/m2 every 2
Page 9 and 10: and demonstrated that patients with
Page 11 and 12: Commentary Optimizing Taxane Therap
Page 13 and 14: HER2 Status and Inflammatory Breast
Page 15 and 16: year OS was 53.1% (95% CI, 44.0%-61
Page 17 and 18: include those related to cell motil
Page 19 and 20: CaseStudy Risk of Local Recurrence
Page 21 and 22: factors such as age and margin stat

Review - Haymarket Media Group

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?